Adenomyosis
Conditions
Interventions
Group 1:A 10.8 mg goserelin acetate sustained-release implant is subcutaneously injected every 12 weeks, and a total of 1-2 injections are given according to the patients condition
Group 2:A 3.6 mg goserelin acetate sustained-release implant is subcutaneously injected every 4 weeks, and a total of 3-6 injections are given according to the patients condition
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
Female
Age
18 Years to 49 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with adenomyosis based on clinical assessment, ultrasound or magnetic resonance imaging (MRI); 2. Women aged 18-49 years; 3. With symptoms of dysmenorrhea and/or menorrhagia ; 4. With good compliance during treatment and can cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating patients; 2. Patients treated with GnRH-a within 3 months; 3. Patients who have received adenomyosis related surgical treatment or interventional treatment; 4. Patients with intrauterine Levonorgestrel intrauterine Sustained-release system (LNG-IUD); 5. Refuse to use GnRH-a; 6. Patients with probable or confirmed uterine malignancy; 7. Patients with GnRH-a contraindication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine;Carbohydrate antigen-125;Uterine volume;Days and volume of uterine bleeding with different degrees;NRS (Numerical rating scale) pain score;Uterine bleeding rate per cycle after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug-related side effects; | — |
Countries
China
Contacts
Public ContactWang Guoyun
Outcome results
None listed